An observational study in Monogenic Obesity, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 2 sites in France. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris — 16 open to participants now, 16 under way, 1 of them phase 3. Obesity · Assistance Publique - Hôpitaux de Paris.
Among the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, this one is the 10th largest by planned enrollment of the 20 observational ones that give a count, is one of 3 that started in 2024, is one of 20 observational ones, reaches primary completion later than 6 of the 15 other live ones, and was the 51st registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →16 of the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–85
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–64 · Women only · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–65
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2024.
This study's planned enrollment of 175 is above the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 110 across the 38 interventional studies, 175 across the 20 observational. Of the 36 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
4 of the studies in Obesity by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06867354Assistance Publique - Hôpitaux de ParisPrevalence, Determinants and Consequences of Dyspnea During Weaning in Critically Ill Obese Patients | 2027-03 |
| NCT06380426Assistance Publique - Hôpitaux de ParisA Multicenter Pharmacoepidemiological Cohort on Real Life Use of Semaglutide in Adolescents or Adults With Monogenic Obesity | 2027-04-30 |
| NCT04893954Assistance Publique - Hôpitaux de ParisProspective Study on the Consequences of Weight Loss After Bariatric Surgery on Obese Patients' Spine. | 2027-07 |
| NCT06899997Assistance Publique - Hôpitaux de ParisStudy of the Effects of Time-Restricted Feeding on the Immune Function of Individuals With Obesity | 2027-09-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Rare genetic forms of obesity, so called monogenic obesity are linked to alteration in energy balance involving hypothalamic pathways.
More than 60 genes encoding for proteins located in the hypothalamic leptin/melanocortin pathway have been described in the French National Protocol for Diagnostic and Care (PNDS).
While pathogenic and likely pathogenic variants in these genes are well-established causes of monogenic obesity, current evidence supports a broader genetic architecture of obesity, better understood as a continuum ranging from rare high-impact variants to polygenic susceptibility.
Variants of uncertain significance (VUS) as well as variants currently classified as benign or likely benign are frequently identified in clinical practice, and their classification may evolve over time as genomic databases expand and functional data accumulate In addition, polygenic background may interact with rare variants and contribute to the severity of the phenotype, disease progression, and therapeutic response.
The natural history of monogenic obesity is characterized by an early onset in childhood, with a major increase in weight in adolescence and young adulthood. The worsening of obesity exposes these patients to severe complications.
Severe obesity and eating disorders have a major impact on the quality of life of the person but also of the family and caregivers. Clinical management is complex and requires comprehensive, specialized and multidisciplinary management. The usual lifestyle approaches have so far shown disappointing results, similarly to bariatric surgery which leads to a more frequent weight regain in the situation of monogenic obesity, justifying new approaches.
In this context, evaluating the response to treatment in the particular condition of monogenic obesity is crucial to propose therapeutic options as early as possible to limit weight evolution and its complications.
GLP-1 (glucagon-like peptide 1) based innovative therapies have recently emerged as a promising option for treatment of obesity and its complications. This is the case for Semaglutide marketed as OZEMPIC® and WEGOVY®, developed by Novo Nordisk. However, there is a lack of data to confirm that semaglutide could be also effective in monogenic obesity.
The aim of the ObGeSema project is to set up a cohort composed of patients (1) having already initiated a treatment and (2) newly treated by Semaglutide in 21 pediatric and adult Specialized Obesity Centres (CSOs) and describe their evolution over a 4 years follow-up.
Rare genetic forms of obesity, so called monogenic obesity are linked to alteration in energy balance involving hypothalamic pathways. More than 60 genes encoding for proteins located in the hypothalamic leptin/melanocortin pathway have been described in the French National Protocol for Diagnostic and Care (PNDS) https://www.has-sante.fr/jcms/p_3280217/fr/generique-obesites-de-causes-rares).
While pathogenic and likely pathogenic variants in these genes are well-established causes of monogenic obesity, current evidence supports a broader genetic architecture of obesity, better understood as a continuum ranging from rare high-impact variants to polygenic susceptibility.
Variants of uncertain significance (VUS) as well as variants currently classified as benign or likely benign are frequently identified in clinical practice, and their classification may evolve over time as genomic databases expand and functional data accumulate In addition, polygenic background may interact with rare variants and contribute to the severity of the phenotype, disease progression, and therapeutic response.
The natural history of monogenic obesity is characterized by an early onset in childhood, with a major increase in weight in adolescence and young adulthood. The worsening of obesity exposes these patients to severe complications. Severe obesity and eating disorders have a major impact on the quality of life of the person but also of the family and caregivers. Clinical management is complex and requires comprehensive, specialized and multidisciplinary management. The usual lifestyle approaches have so far shown disappointing results, similarly to bariatric surgery which leads to a more frequent weight regain in the situation of monogenic obesity, justifying new approaches.
In this context, evaluating the response to treatment in the particular condition of monogenic obesity is crucial to propose therapeutic options as early as possible to limit weight evolution and its complications.
GLP-1 based innovative therapies have recently emerged as a promising option for treatment of obesity and its complications. This is the case for Semaglutide marketed as OZEMPIC® and WEGOVY®, developed by Novo Nordisk. However, there is a lack of data to confirm that semaglutide could be also effective in monogenic obesity, particularly across the full spectrum of genetic variants involved in the leptin-melanocortin pathway.
In France, semaglutide is currently accessible through several regulatory frameworks:
OZEMPIC® (up to 2 mg/week) is reimbursed by the French Social Security for the treatment of type 2 diabetes in adult patients.
WEGOVY® (up to 2.4 mg/week) was available through an Early Access Programme from May 2022 to September 2024 for adults with BMI >40 kg/m² and at least one comorbidity. Treatment initiated in this framework can be continued until December 2025.
Since November 2024, WEGOVY® (up to 2.4 mg/week) has had marketing authorization for the treatment of adolescents and adults ≥12 years with BMI ≥30 kg/m². However, the drug is not yet reimbursed, except in rare cases through individual exceptional reimbursement for rare and complex diseases.
Given this evolving regulatory landscape, it is essential to assess the real-life efficacy and safety of semaglutide in individuals with including both adolescents and adults carrying variants across the continuum of genetic susceptibility.
The aim of the ObGeSema project is to set up a cohort composed of patients (1) having already initiated a treatment and (2) newly treated by Semaglutide in 21 pediatric and adult Specialized Obesity Centres (CSOs) and describe their evolution over a 4 years follow-up.
Patients (≥12 years) with monogenic obesity due to any variant regardless of pathogenicity classification and already treated or with the physician's decision to initiate treatment with Semaglutide in the standard care. Patients under legal protection and State Medical Assistance (AME) will be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Change in weight and Body Mass Index (BMI)
Percentage of subjects with a change in weight and Body Mass Index (BMI).Weight will be measured at initiation and at 12 months of the Semaglutide treatment
Time frame: From baseline (T0) to T12
Change in weight and Body Mass Index (BMI)
Percentage of subjects with a change in weight and Body Mass Index (BMI). Weight will be measured at initiation of the Semaglutide treatment and at each visit
Time frame: From baseline (T0) to 6 and/or 24 and/or 36 and/or 48 and/or 60 months
Reduction of body weight equal to or above 5%
Percentage of subjects achieving a reduction of body weight equal to or above 5%(number of subjects with a % of body weight changes \> -5%)X100/ number of the total subject
Time frame: From baseline (T0) to 6 and/or 12 and/or 24 and/or 36 and/or 48 and/or 60 months
Change in Hunger score
Number and percentage of subjects with change in Hunger score
Time frame: From baseline (T0) to 12 and/or 24 and/or 36 and/or 48 and/or 60 months
Change in eating behaviour measured by Food Craving questionnaire
Number and percentage of subjects with change in Food Craving scale
Time frame: From baseline (T0) to 12 months
Change in eating behaviour measured by the Binge Eating Scale (BES)
Number and percentage of subjects with change in Binge Eating Scale (BES)
Time frame: From baseline (T0) to 12 months
Change in eating behaviour measured by the Dutch Eating Behaviour Questionnaire (DEBQ)
Number and percentage of subjects with change in Dutch Eating Behaviour Questionnaire (DEBQ)
Time frame: From baseline (T0) to 12 months
Change in eating behaviour measured by the Dykens questionnaire for ≥18 years patients
Number and percentage of subjects with change in Hyperphagia score with the Dykens questionnaire for intellectual disability
Time frame: From baseline (T0) to 12 months
Change in eating behaviour measured by the Child Eating Behaviour Questionnaire (CEBQ)
Number and percentage of subjects with change in the Child Eating Behaviour Questionnaire (CEBQ) for intellectual disability for ≥18 years patients
Time frame: From baseline (T0) to 12 months
Change in the International physical activity questionnaire (IPAQ - short form) for ≥18 years patients
Number and percentage of subjects with change of the International physical activity
Time frame: From baseline (T0) to 12 months
Change in Digestive disorders (GIQLI ) for ≥18 years patients
Number and percentage of subjects with change in Digestive disorders (GIQLI ). Digestive disorders are measured by the Gastrointestinal Quality of Life Index (GIQLI)
Time frame: From baseline (T0) to 12 and/or 24 and/or 36 and/or 48 and/or 60 months
Change in score of quality of life scores (patient and parents) for ≥18 years patients
Number and percentage of subjects with change in score of quality of life scores .Quality of life is measured with the Impact of Weight on Quality of Life-Lite scale (IWQOL-Lite)
Time frame: From baseline (T0) to 12 months
Change in sleep disorder (MCTQ score) for ≥18 years patients
Number and percentage of subjects with Change in sleep disorder. Sleep disorder is measured with the Micro Munich Chronotype Questionnaire (MCTQ)
Time frame: From baseline (T0) to 12 months
Change in anxiety and depression score for ≥18 years patients
Number and percent of subjects with change in anxiety and depression score. Anxiety and depression is measured with the Hospital Anxiety and Depression scale (HAD)
Time frame: From baseline (T0) to 12 and/or 24 and/or 36 and/or 48 and/or 60 months
● Change in Body Mass Index : BMI Z-score for 12 to <18 years
Weight will be measured at initiation of the Semaglutide treatment and at each visit
Time frame: From baseline (T0) to 6 and/or 12 and/or 24 and/or 36 and/or 48 and/or 60 months
Change in eating behaviour scores CEBQ ( Child Eating Behaviour Questionnaire) or Hyperphagia score with the Dykens questionnaire and for intellectual disability. For 12 to <18 years patients
Number and percentage of subjects with change
Time frame: From baseline (T0) to 12 months
Change in score of IWQOL Impact of Weight on Quality of Life (patient and parents). For 12 to <18 years patients
Number and percentage of subjects with change in score Impact of Weight on Quality of Life
Time frame: From baseline (T0) to 12 months
Change in Digestive disorders GIQLI score (Gastrointestinal Quality of Life Index). For 12 to <18 years patients
Number and percentage of subjects with change
Time frame: From baseline (T0) to 12 and/or 24 and/or 36 and/or 48 and/or 60 months
Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Number of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time frame: From baseline (T0) to 6 and/or 12 and/or 24 and/or 36 and/or 48 and/or 60 months
Plan to share: Yes — Data are available upon reasonable request. The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.
Supporting information: Study protocol, Informed consent form
Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor
Access criteria: Researchers who provide a methodological sound proposal.
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Apr 2027, 31 months after the start.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 31 months is below that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →